Sunday, January 15, 2017 1:16:54 AM
Do either of you have a sense for exactly how unusual or extraordinary the Emricasan statistical results are coming out of phase 2/2a? It is my understanding that only 20% of gastroenterological compounds graduate from phase 2 to FDA approval. Are most compounds showing promise similar to Emricasan at this stage of clinical trials or is there something specifically efficacious about Emricasan -- aside from its relevance to treating liver cirrhosis -- that separates it from the pack (thereby increasing its odds of receiving FDA approval)?
Additionally, do either of you have a sense for how savvy Novartis is at evaluating and investing in developmental stage compounds? Does its track record suggest that Emricasan is a low-risk flier for the company in a big potential NASH market or a more significant commitment?
Thanks in advance for your perspective.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM